Last reviewed · How we verify
AREXVY
Arexvy, developed by Clover Biopharmaceuticals AUS Pty, is a marketed drug with an unknown mechanism of action. The key composition patent for Arexvy is set to expire in 2028, providing a clear timeline for potential generic competition. The primary risk is the lack of detailed clinical trial results and revenue data, which may limit investor confidence and market adoption.
At a glance
| Generic name | AREXVY |
|---|---|
| Sponsor | Clover Biopharmaceuticals AUS Pty |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
| Annual revenue | 1500 |
Approved indications
Common side effects
- Injection site pain
- Myalgia
- Fatigue
- Headache
- Arthralgia
- Fatigue
- Myalgia
- Headache
- Arthralgia
- Erythema
- Swelling
- Fatigue
Key clinical trials
- Addressing Unfunded Vaccines Through a Co-payment Mechanism in Pharmacies (NA)
- Vaccine Responses in Patients With B Cell Malignancies (PHASE4)
- Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons (PHASE2)
- RSV Vaccine in Transplant Recipients (PHASE3)
- Immunogenicity of RSV Vaccines in Residents of Long-Term Care Facilities (LTCF) (PHASE4)
- RSV Immunogenicity Study in the Elderly (RISE) (PHASE3)
- A Study of RSV-HMPV Bivalent Vaccine VXB-241 in Older Adults (PHASE1)
- A Study of IVX-A12 in Adults Participants (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AREXVY CI brief — competitive landscape report
- AREXVY updates RSS · CI watch RSS
- Clover Biopharmaceuticals AUS Pty portfolio CI